<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736450</url>
  </required_header>
  <id_info>
    <org_study_id>462-07</org_study_id>
    <secondary_id>NCI-2009-01692</secondary_id>
    <secondary_id>P30CA036727</secondary_id>
    <nct_id>NCT00736450</nct_id>
  </id_info>
  <brief_title>Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>Investigator Initiated Pilot Study of Microarray Directed Therapy for Diffuse Large B-cell Lymphoma Using Genasense With CHOP-R</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Oblimersen sodium may
      help chemotherapy work better by making cancer cells more sensitive to the drugs. Giving
      oblimersen sodium together with combination chemotherapy may kill more cancer cells. PURPOSE:
      This clinical trial is studying the side effects of giving oblimersen sodium together with
      combination chemotherapy and to see how well it works in treating patients with newly
      diagnosed stage I, stage II, stage III, or stage IV diffuse large B-cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To assess the feasibility and determine the rate of rapid turn around,
      that is within 7 working days of receipt of adequate tissue at UNMC for a AFFYmetrix
      microarray study of newly diagnosed patients with Diffuse Large B-cell Lymphoma (DLBCL) who
      will then receive treatment on this protocol. II. To evaluate efficacy (complete response
      rate) of Genasense (antisense bcl-2) given in addition to standard cyclophosphamide,
      vincristine, doxorubicin, and prednisone -rituximab (CHOP-R) to newly diagnosed patients with
      DLBCL who are found to have the ABC type after gene expression profiling or IHC as compared
      to newly diagnosed patients with DLBCL who do not express the ABC type that go on to receive
      standard CHOP-R (control). III. To evaluate the toxicity of Genasense (antisense bcl-2) given
      in addition to standard cyclophosphamide, vincristine, doxorubicin, and prednisone -rituximab
      (CHOP-R) for newly diagnosed patients with DLBCL who are found to have the ABC type after
      gene expression profiling. OUTLINE: Patients with diffuse large B-cell lymphoma (DLBCL) that
      expresses ABC type proceed to treatment in group I. Patients with DLBCL that does not express
      ABC type proceed to treatment in group II. GROUP I (oblimersen sodium and standard CHOP-R):
      Patients receive oblimersen sodium IV continuously on days 1-7. Patients also receive CHOP-R
      comprising rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine
      sulfate IV on day 5 and prednisone orally on days 5-10. Treatment repeats every 3 weeks for
      up to 8 courses in the absence of disease progression or unacceptable toxicity. GROUP II
      (standard CHOP-R alone): Patients receive CHOP-R comprising rituximab IV, cyclophosphamide
      IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1 and prednisone orally
      on days 1-5. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease
      progression or unacceptable toxicity. After completion of study therapy, patients are
      followed periodically.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Manufacturer is no longer making the drug.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Perform Microarray Study After Receipt of Tissue</measure>
    <time_frame>Upto 14 days</time_frame>
    <description>The time from tissue harvest to release of microarray test and IHC assay results will be noted in days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Microarray Testing Results Are Completed Within 7 Days.</measure>
    <time_frame>Upto 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Treatment, in Terms of Complete Response Rate (Anyone Achieving a CR or Cru)</measure>
    <time_frame>End of treatment, an average of 4 months</time_frame>
    <description>Response criteria are the recommendations of the International Harmonization Project's update to the International Working Group guidelines. Complete response (CR) is defined as disappearance of all evidence of disease; Partial response (PR) is defined as regression of measurable disease and no new sites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Contiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage I Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage III Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Stage IV Adult Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>augmerosen</other_name>
    <other_name>G3139</other_name>
    <other_name>G3139 bcl-2 antisense oligodeoxynucleotide</other_name>
    <other_name>Genasense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>DeCortin</other_name>
    <other_name>Deltra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>gene expression profiling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients with Diffuse Large B-cell Lymphoma (DLBCL) (any stage) OR
             composite lymphoma with &gt;= 50% DLBCL

          -  Adequate diagnostic tissue for microarray gene expression analysis or IHC analysis

          -  Karnofsky Performance Status &gt;= 70 (ECOG 0, 1)

          -  No prior chemotherapy (with the exception of 1 cycle CHOP-R based on current
             diagnosis, clinical condition, and availability/feasibility of initiating Genasense),
             immunotherapy, radiotherapy, or investigational therapies for NHL; steroid therapy is
             allowed only if required for maintenance of another chronic disease (e.g., rheumatoid
             arthritis)

          -  Patients aged &gt;= 60 years, or patients with a history of coronary artery disease,
             congestive heart failure, hypertension, diabetes, or hyperlipidemia must have an
             estimated ejection fraction &gt;= 0.45 (45%) by MUGA or echocardiography, performed
             within two months of study entry

          -  Patients must be willing to give written informed consent, and sign an institutionally
             approved consent form prior to initiating genasense or any study related activities
             (i.e., Genasense &amp; microarray)

          -  Females of childbearing potential must have a negative serum pregnancy test prior to
             enrollment in the study

          -  Adequate venous access for 7-day continuous infusion

          -  Patients without evidence of severe organ dysfunction as determined within two weeks
             of 1st cycle of CHOP-R: 1) Hemoglobin &gt; 8 g/dl; 2) Absolute neutrophil count &gt; 1000/;
             3) Platelets &gt; 100,000 (lower blood counts may be acceptable if due to lymphoma after
             review with principal investigator); 4) Creatinine =&lt; 2.0 mg/dL (unless due to NHL);
             5) Bilirubin =&lt; 2.0 mg/dL; 6) AST =&lt; 3 x upper normal; 7) ALP =&lt; 3 x upper normal
             (unless due to NHL)

          -  Men and women of reproductive potential must agree to use TWO of the following forms
             of birth control every time they have sex throughout the study and for up to 3 months
             following discontinuation of study drug: hormonal birth control methods, condoms (male
             or female) with or without a spermicidal agent, diaphragm or cervical cap with
             spermicidal, IUD, or surgical sterilization while participating in this study

        Exclusion Criteria:

          -  Significant medical disease other than cancer including: 1) Any bleeding or
             coagulation disorder including a history of autoimmune hemolytic anemia or autoimmune
             thrombocytopenia; 2) Severe pulmonary disease; 3) Uncontrolled congestive heart
             failure; 4) New York Heart Association class III or IV disease; 5) Uncontrolled
             seizure disorder; and 6) Active infections

          -  Less than 3 weeks from prior major surgery

          -  Prior organ allograft

          -  Known HIV infection (due to expected frequent occurrence of myelo-suppression and
             immunosuppression)

          -  Women who are pregnant (confirmed by a serum pregnancy test in females of reproductive
             potential) or breast-feeding (women of child-bearing potential and sexually active
             males must be advised to take precautions to prevent pregnancy during treatment or
             remain abstinent)

          -  Women of child-bearing potential and sexually active males must be advised to take
             precautions to prevent pregnancy during treatment (unless the subject or subject's
             partner(s) is sterile, i.e., women who have had a hysterectomy or have been
             post-menopausal for at least twelve consecutive months) or remain abstinent

          -  Known hypersensitivity to phosphorothiate-containing oligonucleotides

          -  Concurrent investigational, corticosteroid therapy or any other anti-cancer treatments
             (such as chemotherapy, radiation, biologic or investigational therapies) while
             receiving protocol therapy; other than one cycle CHOP-R allowed based on current
             diagnosis, clinical condition, and availability/feasibility of initiating Genasense;
             other than chronic steroid use for another indication (For stage I/II or as clinically
             indicated- involved field irradiation as per standard practice is accepted)

          -  Other investigational drug therapy within 30 days of study entry

          -  Secondary leukemia or history of antecedent hematologic disorder

          -  History of second cancer (except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, or other cancer for which the patient has been
             disease-free for three or more years)

          -  No active CNS disease defined as symptomatic meningeal lymphoma or known CNS
             parenchymal lymphoma

          -  Concomitant anticoagulant therapy is not permitted (with the exception of 1 mg/day of
             warfarin for central line prophylaxis)

          -  Known hypersensitivity to G3139 (Genasense) or R-CHOP

          -  Neurologic disorders, overt psychosis, mental disability or evidence of limited
             capacity to provide fully informed consent or cooperation with the complexities of the
             treatment program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Vose</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 14, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>January 30, 2018</results_first_submitted>
  <results_first_submitted_qc>August 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2018</results_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Julie M Vose, MD</investigator_full_name>
    <investigator_title>Neumann M. and Mildred E. Harris Professor, Chief, Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 37 subjects consented, 19 were Not ABC gene type positive so were removed from the study.
Of the 18 remaining eligible, 4 patients opted for standard of care and withdrew from the study.
13 subjects had microarray analysis conducted with tissue.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not ABC gene eligible</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The mean age was calculated from only the 14 subjects that received study treatment.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="30" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Perform Microarray Study After Receipt of Tissue</title>
        <description>The time from tissue harvest to release of microarray test and IHC assay results will be noted in days.</description>
        <time_frame>Upto 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Perform Microarray Study After Receipt of Tissue</title>
          <description>The time from tissue harvest to release of microarray test and IHC assay results will be noted in days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Microarray Testing Results Are Completed Within 7 Days.</title>
        <time_frame>Upto 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Microarray Testing Results Are Completed Within 7 Days.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>results within 7 days or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>results in more than 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Treatment, in Terms of Complete Response Rate (Anyone Achieving a CR or Cru)</title>
        <description>Response criteria are the recommendations of the International Harmonization Project's update to the International Working Group guidelines. Complete response (CR) is defined as disappearance of all evidence of disease; Partial response (PR) is defined as regression of measurable disease and no new sites</description>
        <time_frame>End of treatment, an average of 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Treatment, in Terms of Complete Response Rate (Anyone Achieving a CR or Cru)</title>
          <description>Response criteria are the recommendations of the International Harmonization Project's update to the International Working Group guidelines. Complete response (CR) is defined as disappearance of all evidence of disease; Partial response (PR) is defined as regression of measurable disease and no new sites</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>complete response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>partial response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants adverse event data was collected from time of initial study drug dosing until completed study treatment. (approximately 6 months)</time_frame>
      <desc>Only reporting all Serious adverse events and Other AEs grade 3 and 4.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients in this study who are found to have the Activated B-Cell (ABC) type after gene expression profiling or Immunohistochemistry (IHC) staining will receive combination chemotherapy with the standard CHOP-R with Genasense (oblimersen) (anti-bcl2 oligonucleotide).
oblimersen sodium: Given IV
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate: Given IV
prednisone: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>thrombocytopenia</description>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>White blood cells decreased</sub_title>
                <description>Leukocyte count decreased</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>low hemoglobin</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <description>reaction to rituxan</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <description>oral infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other</sub_title>
                <description>opportunistic infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>maxillary</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <description>Thrombus- right arm related to PIC line.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other</sub_title>
                <description>infection, port site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>leukocytes</description>
                <counts group_id="E1" events="22" subjects_affected="10" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="10" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>deep vein thrombosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julie Vose, MD</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-3848</phone>
      <email>jmvose@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

